Journal Article Ppublish 12 citations
PubMed: 38377325 DOI: 10.1089/dia.2023.0432
Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems.
Diabetes Technol Ther 26(S3):102-106
Authors: Halis K Akturk, Tadej Battelino, Javier CastaƱeda, Arcelia Arrieta, Tim van den Heuvel, Ohad Cohen
Affiliations
- Barbara Davis Center for Diabetes, University of Colorado, Aurora, Colorado, USA.
- University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
- Medtronic International Trading SĆ rl, Tolochenaz, Switzerland.
Abstract
The concept of maintaining blood glucose levels within the 70-180āmg/dL range, known as time-in-range, has raised questions regarding its representation of true physiological euglycemia. Some have speculated that focusing on the time spent within the 70-140āmg/dL range, introduced as time in tight range (TITR) through the International Consensus statement, could serve as a more precise metric for assessing normoglycemia in individuals with type 1 diabetes. This article delves into the current status of TITR as an emerging marker and explores how advanced hybrid closed-loop systems may offer a promising avenue for achieving this higher level of glycemic control.
MeSH
Insulin
Cited by
- International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024 Diabetes Technologies: Glucose Monitoring. Horm Res Paediatr, 2025
- Association between time in tight range and incident diabetic retinopathy in adults with type 2 diabetes. Diabetes Obes Metab, 2025